Poet Research vs. Hydrite Chemical: Mycotoxin Patent Case Transferred to Wisconsin After 601 Days
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Poet Research, Inc. v. Hydrite Chemical Company |
| Case Number | 1:24-cv-01285 (N.D. Ill.) / Transfer to E.D. Wis. |
| Court | Northern District of Illinois (transferred to Eastern District of Wisconsin) |
| Duration | Feb 2024 – Oct 2025 601 days (in N.D. Ill.) |
| Outcome | Transfer Order – Improper Venue & Jurisdiction |
| Patents at Issue | |
| Accused Products | Hydrite Chemical CB-400, CB-427, 2216 product lines |
Case Overview
The Parties
⚖️ Plaintiff
A leading innovator in biofuel and agricultural biotechnology, specializing in fermentation efficiency, grain quality, and mycotoxin management solutions.
🛡️ Defendant
A Wisconsin-based specialty chemical manufacturer serving agricultural, food, and industrial markets with solutions for mycotoxin reduction.
The Patents at Issue
This dispute revolves around four U.S. patents held by Poet Research, which allegedly cover technologies for reducing mycotoxins, specifically deoxynivalenol (DON), in agricultural products and processing streams:
DON is a significant mycotoxin impacting grain quality and livestock feed safety, making effective mitigation technology a commercially valuable area.
Developing mycotoxin solutions?
Ensure your products don’t infringe on existing patents.
The Verdict & Legal Analysis
Outcome of Illinois Proceedings
The case did not proceed to a decision on patent infringement, validity, or damages in the Northern District of Illinois. Instead, on October 8, 2025, the court ordered the transfer of the entire case to the Eastern District of Wisconsin based on a ruling concerning venue and personal jurisdiction.
Venue & Jurisdictional Ruling
Chief Judge Andrea R. Wood found that the Northern District of Illinois was an improper venue for this litigation and that the court lacked personal jurisdiction over Hydrite Chemical Company. Citing the Supreme Court’s decision in *TC Heartland LLC v. Kraft Foods Group Brands LLC*, the court emphasized that patent venue requires the defendant to be incorporated in the district or to have committed acts of infringement AND maintain a regular and established place of business there.
Hydrite, being a Wisconsin-based company, did not meet these criteria for the Illinois forum. Poet Research’s subsequent non-opposition to transfer to the Eastern District of Wisconsin allowed for a more efficient resolution of the venue dispute.
Filing a new mycotoxin patent?
Learn from this case. Use AI to draft stronger claims that can withstand litigation.
Power Your IP Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in the mycotoxin reduction market. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this venue ruling and ongoing litigation.
- View all 4 patents asserted in this litigation
- See companies active in mycotoxin reduction patents
- Understand claim construction patterns in this tech space
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your mycotoxin reduction technology or product details
- AI identifies potentially blocking patents
- Get actionable risk assessment report
Venue Risk
Improper venue can delay litigation by over 600 days.
4 Asserted Patents
From Poet Research’s portfolio.
Active Litigation
Case now proceeding in Wisconsin.
✅ Key Takeaways
For Patent Litigators
The strict venue requirements under 28 U.S.C. § 1400(b) post-*TC Heartland* demand rigorous pre-filing analysis, especially for defendants incorporated outside the chosen district.
Search venue case law →Early jurisdictional challenges remain a potent defense strategy to delay or redirect litigation, potentially costing plaintiffs years and significant resources.
Explore defense strategies →For R&D and IP Teams
The active assertion of four patents in the mycotoxin reduction space signals an aggressive IP enforcement environment. Conduct FTO analysis before commercializing related technologies.
Start FTO analysis for my product →Understand the claims of patents like US11882861B2 and related patents to identify potential infringement risks or opportunities for design-arounds.
View US11882861B2 claims →Ready to Strengthen Your IP Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.